Owada, S
How tirzepatide works: the GLP-1 and GIP dual agonist Tirzepatide changed the game by adding a second receptor target: glucose-dependent insulinotropic polypeptide (GIP)
NNMT inhibition with 5-Amino-1MQ reduced white adipose tissue mass by ~35% in diet-induced obese mouse models without suppressing food intake, suggesting energy expenditure modulation
[1] These medications work by mimicking the action of naturally occurring GLP-1, an incretin hormone that stimulates insulin secretion in response to food intake, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways
Patients should be prepared to discuss medical history, current medications, previous treatments, wellness goals, and recent lab work if available
Clear communication ensures you get the support you need